Trials / Conditions / Tourette's Disorder

Tourette's Disorder

18 registered clinical trials studyying Tourette's Disorder — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Remote Delivery of a Mindfulness-based Intervention for Tics NCT06408662	Johns Hopkins University	N/A
Recruiting	Forehead Temperature-Regulating Therapy for Insomnia in Adults With Tourette's Disorder NCT05499741	University of California, Los Angeles	N/A
Completed	Internet-delivered Behaviour Therapy for Children and Adolescents With Tourette's Disorder NCT03916055	Karolinska Institutet	N/A
Completed	Investigating Circadian Rhythms in Youth With Persistent Tic Disorders NCT03508245	University of California, Los Angeles	N/A
Completed	Internet-based Behaviour Therapy for Tourette's Disorder and Chronic Tic Disorder NCT02864589	Karolinska Institutet	N/A
Completed	TicHelper: A Computerized Comprehensive Behavioral Intervention for Tics (CBIT) NCT02413216	University of Utah	N/A
Completed	Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder NCT01727713	Otsuka Pharmaceutical Development & Commercialization, Inc.	Phase 3
Completed	Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescent NCT01727700	Otsuka Pharmaceutical Development & Commercialization, Inc.	Phase 3
Completed	Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder NCT01585207	Barbara J. Coffey	Phase 1 / Phase 2
Completed	ABF Tourette's Disorder Post Marketing Surveillance Study NCT01795105	Korea Otsuka Pharmaceutical Co., Ltd.	—
Completed	Psychosocial Intervention for Young Children With Chronic Tics NCT03042507	Weill Medical College of Cornell University	N/A
Completed	Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Dis NCT01416441	Otsuka Pharmaceutical Development & Commercialization, Inc.	Phase 3
Completed	Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder NCT01418352	Otsuka Pharmaceutical Development & Commercialization, Inc.	Phase 3
Completed	Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder NCT01418339	Otsuka Pharmaceutical Development & Commercialization, Inc.	Phase 3
Completed	Assessment of Children With Tic Onset in the Past 6 Months NCT01177774	Washington University School of Medicine	—
Completed	Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder NCT00706589	Korea Otsuka Pharmaceutical Co., Ltd.	Phase 3
Completed	Internet-based Coaching for Young Adults With Neuropsychiatric Disorders NCT02316145	Vardalinstitutet The Swedish Institute for Health Sciences	N/A
Completed	Omega-3 Fatty Acids in Tourette's Disorder NCT01315327	NYU Langone Health	N/A